CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

In this clinical trial, Medicortex seeks to collect a sufficient number of pediatric samples in order to prove the applicability of the brain injury test in children, as a natural continuation for previously proven clinical performance in adults.

Valencia Technologies announced 6-month interim efficacy data from its eCoin Pivotal Clinical Trial. The announcement follows the podium presentation of the interim data at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) 2020 Annual Meeting on February 28th, 2020.

This first-in-human clinical study is conducted to validate the suprachoroidally placed EYEMATE-SC sensor implant for continual monitoring of intraocular pressure (IOP). The lead investigator Prof. Dr. med. Peter Szurman from Eye Sulzbach at Knappschaft Hospital Saar, Germany asserts: “The eye pressure sensor is pleasantly small and easy to implant, so most patients undergoing glaucoma surgery are eligible for such a pressure sensor. This enables glaucoma patients for the first time to monitor their own eye pressure at any time. It will improve the safety for glaucoma patients and significantly reduce the risk of blindness due to glaucoma.”

CorTechs Labs evaluated the performance of these models for identifying MS subjects and studied the differences of feature importance selected by the models based on whole and specific age range data.

Ra Medical received investigational device exemption (IDE) approval for the atherectomy clinical study from the FDA in January 2020.

PROMISE Sensor Clinical Study is to evaluate the safety and efficacy of the Eversense CGM System in people with diabetes over a 180-day period for the pre-market application submission to the U.S.

Peregrine Post-Market Study is a European multicenter open-label trial that evaluated additional safety and performance of the Peregrine System Infusion Catheter using a neurolytic agent (dehydrated alcohol) delivered into the space outside of the renal (kidney) arteries in 45 patients with systemic hypertension.

Note: In December 2019, the company completed a record-breaking Series B funding round of 31 million euros intended to support its launch strategy in major international markets (particularly in Europe and the United States).

The paper demonstrated that using VasQ as the standard of care for radiocephalic fistulas resulted in a significant improvement in his center’s primary fistula failure and longer-term secondary patency rates with less repeat interventions when compared to historical controls.